Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,452 signal articles · 143 in last 24h · 154,112 total before filter · latest 1h ago
143last 24h
876last 7d
147● bullish (7d)
98● bearish (7d)
214publishers
AllMacro210Earnings108M&A125Regulatory22Product21Analyst17
✕ clear all filtersticker: GENBSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)
Insider Monkey93d agoneutral
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)

Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On May 14, Morgan Stanley increased its price objective on Generate Biomedicines, Inc. (NASDAQ:GENB) to $22 from $20. The firm maintained an “Overweight” rating on the shares. Separately, Generate Biomedicines, Inc. (NASDAQ:GENB)’s GB-0895 (anti-TSLP) program […]